following an abbreviated submission:
upadacitinib (Rinvoq®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice630KB (PDF)
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2510
- Indication:
Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response or were intolerant to either conventional therapy (CT) or a biologic agent.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 October 2022